Arrhythmogenic Right Ventricular Cardiomyopathy
24
8
8
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 24 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (24)
FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))
Mayo AVC Registry and Biobank
Arrhythmogenic Activity During Exercise in ARVC Patients
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
DNA Analysis From Isolated Cardiomyocytes in the Molecular Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
Pediatric Cardiomyopathy Mutation Analysis
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Pilot Randomized Trial With Flecainide in ARVC Patients
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
Low QRS Voltages in Young Healthy Individuals and Athletes
Athlete's Heart or Arrhythmogenic Right Ventricular Cardiomyopathy: Contribution of Exercise Cardiovascular Magnetic Resonance (CMR)
South Asian Arrhythmogenic Cardiomyopathy Registry
Registry of Unexplained Cardiac Arrest
National ARVC Data Registry and Bio Bank
Long Term Monitoring for Risk of Sudden Death
Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome
Sahlgrenska Cardiomyopathy Project
PET-detected Myocardial Inflammation is a Characteristic of Cardiac Sarcoid But Not of ARVC